연구성과로 돌아가기
2023 연구자 정보 (852 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Lee, Junglim (Lee, J) |
Daegu Fatima Hosp, Div Hematol Oncol, Ctr Canc, Daegu, South Korea |
|
|
[JCR상위 35.6] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Lee, Myung-Won (Lee, MW) |
Chungnam Natl Univ Hosp, Daejeon, South Korea |
|
|
[JCR상위 35.6] Dynamic risk model: a novel approach incorporating functional high risk factors for predicting survival outcomes in patients with relapsed/refractory multiple myeloma [JCR상위 35.6] Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia [JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) |
SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Lee, Sang Hwan (Lee, SH) |
Daegu Fatima Hosp, Daegu, South Korea |
|
|
[JCR상위 35.6] Clinical outcomes of older patients aged 80 and over with newly diagnosed multiple myeloma | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Lee, Seung-Shin (Lee, SS) |
Wonkwang Univ Hosp, Dept Hematol Oncol, Iksan, South Korea Wonkwang Univ Hosp, Iksan, South Korea |
F-6974-2013 Lee, Jung-Hye |
|
[JCR상위 35.6] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study [JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) [JCR상위 1.5] Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) |
SCIE | 1.5 |
HEMATOLOGY;ONCOLOGY HEMATOLOGY |
|||
|
Lee, Yoojin (Lee, Y) |
Univ Ulsan, Dept Internal Med, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea |
AAB-9799-2022 Lee, Yoojin |
|
[JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Park, Sung-Soo (Park, SS) |
Catholic Univ Korea, Seoul St Marys Hematol Hosp, Dept Hematol, Coll Med, Seoul, South Korea |
MBG-1896-2025 Park, Young Sik |
|
[JCR상위 35.6] Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Park, Sungwoo (Park, S) |
Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju Si, South Korea |
|
|
[JCR상위 35.6] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Park, Young Hoon (Park, YH) |
Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea Ewha Womans Univ, Mokdong Hosp, Seoul, South Korea |
CZZ-0090-2022 Park, Jung Hoon |
|
[JCR상위 35.6] Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean multiple myeloma working party (KMM 2202) [JCR상위 35.6] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study [JCR상위 1.5] A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study |
SCIE | 1.5 |
HEMATOLOGY;ONCOLOGY HEMATOLOGY |
|||
|
Sohn, Sang-Kyun (Sohn, SK) |
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Sch Med, Daegu, South Korea Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea |
|
|
[JCR상위 35.6] Dynamic risk model: a novel approach incorporating functional high risk factors for predicting survival outcomes in patients with relapsed/refractory multiple myeloma [JCR상위 35.6] Differential DNA mutation profiles in multiple myeloma patients: implications of PET/CT findings [JCR상위 74.3] Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [JCR상위 28.4] Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor [JCR상위 28.1] Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma (vol 38, pg 238, 2023) [JCR상위 28.1] Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma |
SCIE ESCI |
28.1 |
HEMATOLOGY;ONCOLOGY MEDICINE, GENERAL & INTERNAL HEMATOLOGY |
sksohn@knu.ac.kr; ihkimmd@snu.ac.kr; jhmoon@knu.ac.kr; |
||
|
Uhm, Ji Eun (Uhm, JE) |
Hanyang Univ, Div Hematol & Oncol, Dept Internal Med, Hanyang Univ Hosp,Coll Med, Seoul, South Korea |
|
|
[JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) | SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Watumlawar, Ega Cyntia (Watumlawar, EC) |
제1저자 | Kyungpook Natl Univ, Dept Wood & Paper Sci, Daegu, South Korea |
|
0009-0002-0191-2717 Watumlawar, Ega Cyntia |
[JCR상위 35.6] Synthesis of acetone-fractionated hardwood kraft lignin-based adhesive crosslinked with epichlorohydrin | SCIE | 35.6 | ENGINEERING, CHEMICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;MECHANICS | byungdae@knu.ac.kr; | |
|
Yhim, Ho-Young (Yhim, HY) |
Jeonbuk Natl Univ Hosp, Jeonju, South Korea Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju, South Korea |
J-1531-2012 Yhim, Ho-Young |
|
[JCR상위 35.6] Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia [JCR상위 1.5] The Co-Occurrence of bZIP in-Frame CEBPA-Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia |
SCIE | 1.5 |
HEMATOLOGY;ONCOLOGY HEMATOLOGY |
|||
|
Yi, Jun Ho (Yi, JH) |
Chung Ang Univ Hosp, Seoul, South Korea Chung Ang Univ, Seoul, South Korea |
GXZ-8144-2022 Yi, Jun Ho |
|
[JCR상위 35.6] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) [JCR상위 49.0] A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study [JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) [JCR상위 1.5] Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) |
SCIE ESCI |
1.5 |
HEMATOLOGY;ONCOLOGY HEMATOLOGY |
kstwoh@skku.edu;drydh1685@hotmail.com; | ||
|
Yoo, Kwai Han (Yoo, KH) |
Gachon Univ, Gil Med Ctr, Seongnam, South Korea Gachon Univ, Gil Med Ctr, Seongnam Si, South Korea |
|
|
[JCR상위 35.6] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) [JCR상위 35.6] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study |
SCIE | 35.6 | HEMATOLOGY;ONCOLOGY | |||
|
Yoon, Dok Hyun (Yoon, DH) |
Univ Ulsan, Asan Med Ctr, Coll Med, Ulsan, South Korea Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea Univ Ulsan, Coll Med, Asan Med Ctr, Ulsan, South Korea Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea |
|
|
[JCR상위 35.6] Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: a nationwide cohort study by the Korean multiple myeloma working party (KMM 2202) [JCR상위 28.4] Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study [JCR상위 35.6] Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia [JCR상위 35.6] Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study) [JCR상위 1.5] Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) |
SCIE | 1.5 |
HEMATOLOGY;ONCOLOGY ONCOLOGY HEMATOLOGY |
ckmin@catholic.ac.kr;hseom@ncc.re.kr; |
페이지 이동: